16 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Synthesis, characterization, and optimization for in vivo delivery of a nonselective isopeptidase inhibitor as new antineoplastic agent.
University of Trieste
X-ray structural and biological evaluation of a series of potent and highly selective inhibitors of human coronavirus papain-like proteases.
Purdue University
Spongiacidin C, a pyrrole alkaloid from the marine sponge Stylissa massa, functions as a USP7 inhibitor.
Kumamoto University
Recent advances in the development of deubiquitinases inhibitors as antitumor agents.
China Pharmaceutical University
The discovery of potent USP2/USP8 dual-target inhibitors for the treatment of breast cancer via structure guided optimization of ML364.
China Pharmaceutical University
Discovery and Characterization of BAY-805, a Potent and Selective Inhibitor of Ubiquitin-Specific Protease USP21.
Bayer
Recent advances in the development of ubiquitin-specific-processing protease 7 (USP7) inhibitors.
Zhengzhou University
Discovery of Potent Small-Molecule USP8 Inhibitors for the Treatment of Breast Cancer through Regulating ERĪ± Expression.
China Pharmaceutical University
Discovery of Potent OTUB1/USP8 Dual Inhibitors Targeting Proteostasis in Non-Small-Cell Lung Cancer.
Fudan University
Discovery of Potent, Selective, and Orally Bioavailable Inhibitors of USP7 with In Vivo Antitumor Activity.
Rapt Therapeutics
Advances in Discovering Deubiquitinating Enzyme (DUB) Inhibitors.
Dana-Farber Cancer Institute
Chemical Approaches to Intervening in Ubiquitin Specific Protease 7 (USP7) Function for Oncology and Immune Oncology Therapies.
Progenra
Development of a highly reliable assay for ubiquitin-specific protease 2 inhibitors.
Shanghai Jiao Tong University
